Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: Meta-analysis of randomised trials

British Medical Journal

Volumn 318, Issue 7191, 1999, Pages 1104-1107

  Knoll, Greg A ^a   Bell, Robert C ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; TACROLIMUS;

ALLOGRAFT; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; META ANALYSIS; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0033599710     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.318.7191.1104     Document Type: Article

References (27)

1. 1 US Renal Data System. USRDS 1997 annual data report. Bethesda, Maryland: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, April 1997.
2. 2 Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short-and long-term kidney graft survival. Transplantation 1995;60:1384-8.
3. 3 Starzl TE, Fung J, Venkataramman R, Todo S, Demetris AJ, Jain A. FK506 for liver, kidney and pancreas transplantation. Lancet 1989;ii:1000-4.
4. 4 Shapiro R, Jordan M, Scantlebury V, Fung J, Jensen C, Tzakis A, et al. FK506 in clinical kidney transplantation. Transplant Proc 1991;23:3065-7.
5. 5 Ochiai T, Ishibashi M, Fukao K, Takahashi K, Endo T, Yokoyama I, et al. Japanese multicenter studies of FK506 in renal transplanlation. Transplant Proc 1995;27:50-3.
6. 6 Cecka JM. The UNOS scientific renal transplant registry. Ten years of kidney transplants. In: Cecka JM, Terasaki PI, eds. Clinical transplants 1997. Los Angeles: Regents of the University of California, 1998.
7. 7 Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977-83.
8. 8 Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee R, Klein B, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997;64:436-43.
9. 9 Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. Transplantation 1996;61:1576-81.
10. 10 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Contr Clin Trials 1996;17:1-12.
11. 11 DerSimonian R, Laird N. Meta-analysis in clinical trials. Contr Clin Trials 1986;7:177-88.
12. 12 Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS. FK506 in kidney transplantation: results of the USA randomized comparative phase III study. Transplant Proc 1997;29:304-5.
13. 13 Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998;65:515-23.
14. 14 Neylan JF. Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. Transplant Proc 1998;30:1355-8.
15. 15 Jensik SC. Tacrolimus (FK506) in kidney transplantation: three-year surviral results of the US multicenter, randomized, comparative trial. Transplant Proc 1998;30:1216-8.
16. 16 Tramer MR, Reynolds DJM, Moore RA, McQuay HJ. Impact of coven duplicate publication on meta-analysis: a case study. BMJ 1997;315:635-40.
17. 17 McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712-20.
18. 18 Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson NH. The impact of acute rejection on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993;56:307-15.
19. 19 Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival. Transplantation 1994;57:857-9.
20. 20 Melosky B, Karim M, Chui A, McBride M, Cameron EC, Yeung CK, et al. Lymphoprolifevative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression. J Am Soc Nephrol 1992;2:S290-4.
21. 21 Oh CS, Stratta RF, Fox BC, Sollinger HW, Belzer FO, Maki DG. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 1988;45:68-73.
22. 22 Scantlebury V, Shapiro R, Fung JJ, Tzakis A, McCauley J, Jordan M, et al. New onset of diabetes in FK506 vs. cyclosporine-treated kidney transplant recipients. Transplant Proc 1991;23:3169-70.
23. 23 Pircsh JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. Reply to commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1998;65:144-5.
24. 24 Chalmers TC, Matta RJ, Smith H, Kunzier AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091-6.
25. 25 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in mela-analyses? Lancet 1998;352:609-13.
26. 26 Khan KS, Daya S, Jadad AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996;156:661-6.
27. 27 Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients. Transplantation 1997;63:39-47.